This article is more than 5 years old. Information may no longer be current.

Johns Hopkins Kimmel Cancer Center announces faculty appointments

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Johns Hopkins Kimmel Cancer Center made the following faculty announcements:

• Satish Shanbhag, MBBS, MPH, has been appointed medical director of the medical oncology/hematology outpatient practice at the Johns Hopkins Bayview Medical Center. He will provide clinical leadership, oversight and direction to faculty members and other clinical team members, including nurses, pharmacists and pharmacy technicians, medical assistants, and social workers.
• Jeffrey S. Huo, MD, PhD, has been appointed instructor of oncology and pediatrics. Huo’s research focuses on epigenetic reprogramming in stem cells and cancer, as well as development of a stem-cell based model of human retinoblastoma.
• Nicolas J. Llosa, MD, has been appointed instructor of oncology and pediatrics. Llosa’s research focus is to analyze colorectal cancers, looking for genetic fingerprints that help the immune system recognize and fight cancer cells. Llosa will use similar strategies to find immune therapy targets in sarcomas.
• Allison Martin, MD, has been appointed instructor of oncology and pediatrics. Martin will continue her work on immunotherapy for medulloblastoma. She also will study PD-L1 expression in a panel of pediatric brain tumors, including high-grade gliomas, in hopes of developing a phase 1 clinical trial of anti-PD–1 therapy in pediatric brain tumors.